Category: Global stocks

Global Stock refer to share that are traded on multiple exchanges with different currencies. For example, if a publicly-traded company issues shares in dollars on the New York Stock Exchange and in pounds on the London Stock Exchange, it is issuing global registered shares. Global stock to a portfolio offers diversification and may provide higher returns. Global stock markets may experience higher levels of volatility than other domestic markets with bigger swings to both the upside and downside.

Categories
Global stocks

The current share price of VRT is largely reflecting the takeover offer from UK based CapVest Partners

Investment Thesis

  • Currently under takeover activity, with an offer from CapVest Partners for $7.60 per share.
  • The Aging Australian population and increased age of mothers (especially with the trend of more females choosing career over family until their early thirties) will provide favourable demographic tailwinds. 
  • Potential accretive acquisitions domestically and internationally. Domestic acquisition of other laboratories will consolidate VRT geographic expansion strategy along the eastern seaboard of Australia. 
  • Earnings increasingly become diversified as international segments are expected to become a larger contributor. 
  • Solid balance sheet with flexibility to execute expansion strategies. 
  • Market-leading position with ~40% of domestic market share.

Key Risks

  • Current takeover activity does not lead to a transaction. 
  • Regulatory risk as changes in government funding may increase patient’s out-of pocket expenses and thereby decrease volume demand. 
  • Fluctuations in the availability and size of Medicare rebates may negatively influence the number of IVF cycles administered and overall industry revenue.
  • Weakening cycle activity continues to adversely impact revenues. 
  • Increased competition from low-cost providers. 
  • Weakening economic activity resulting in increased unemployment leading to less disposable income to be spent in IVF treatment. 
  • Execution of international forays goes poorly.

Key Highlights: Relative to the pcp and on a constant currency basis: 

  • Revenue increased +1% to $171.3m, however, EBITDA and NPAT declined -36% and -50% to $37.9m and $15.2m, respectively, primarily due to higher operating expenses, margin erosion from cancelled/deferred cycles during the period and pcp including $7.7m of Covid-19 related Government assistance and a fair value gain of $1.6m on a contingent consideration vs $2.6m of M&A transaction costs in current period. 
  • Net debt declined -19% over 2H21 to $76.5m, leading to leverage improving to 1.3x. 
  • The Board declared a fully franked interim dividend of 12cps, representing a payout ratio of ~65%. However, the Board expects a 2H22 dividend to be based on a full year dividend range of 45-55% to enhance balance sheet flexibility for investment in organic and inorganic growth initiatives.
  • Australia revenue increased +1.8% driven by fresh IVF cycles growth of +1.3%. Premium service volumes (~80-85% of revenue) increased +1.2% with growth in all regions, The Fertility Centre (TFC) volumes (~15-20% of revenue) increased +1.7% (remained severely disrupted by the prolonged lockdowns), Fertility diagnostic revenue increased +8.5% amid growth of Preimplantation Genetic Testing (PGT) activity, and Day Hospitals revenue increased +4.3% amid improvement in demand for non-IVF procedures, which now account for ~50% revenue. Segment EBITDA declined -21% amid higher employee costs reflecting expansion of the workforce and Covid-19 related cancelled/deferred cycles.
  •  International revenue declined -2% and EBITDA declined – 19% with Singapore down -18% (fresh cycle volumes down -16.3%), Denmark down -24% (fresh cycle volumes down -8.4%), Ireland down -14% (fresh cycle volumes increase of +0.8% more than offset by preconception genetic screening roll out delays and constraints on egg donation program) and U.K. down -11%.

Company Description

Virtus Health Ltd (ASX: VRT) is a global provider of assisted reproductive services. The group’s main activity is providing patients with Assisted Reproductive Services such as specialized diagnostics, fertility clinics and day hospital services. It has 116 fertility specialists who are supported by over 1100 professional staff and is the largest network and provider of fertility services in Australia and Ireland, with a growing presence in Singapore. Virtus is one of three major players which collectively control more than 80% of market share and was the first infertility treatment company in the world to float on the stock market.

DISCLAIMER for General Advice: (This document is for general advice only).

This document is provided by Laverne Securities Pty Ltd T/as Laverne Investing. Laverne Securities Pty Ltd, CAR 001269781 of Laverne Capital Pty Ltd AFSL No. 482937.

The material in this document may contain general advice or recommendations which, while believed to be accurate at the time of publication, are not appropriate for all persons or accounts. This document does not purport to contain all the information that a prospective investor may require.  The material contained in this document does not take into consideration an investor’s objectives, financial situation or needs. Before acting on the advice, investors should consider the appropriateness of the advice, having regard to the investor’s objectives, financial situation, and needs. The material contained in this document is for sales purposes. The material contained in this document is for information purposes only and is not an offer, solicitation or recommendation with respect to the subscription for, purchase or sale of securities or financial products and neither or anything in it shall form the basis of any contract or commitment. This document should not be regarded by recipients as a substitute for the exercise of their own judgment and recipients should seek independent advice.

The material in this document has been obtained from sources believed to be true but neither Laverne and Banyan Tree nor its associates make any recommendation or warranty concerning the accuracy or reliability or completeness of the information or the performance of the companies referred to in this document. Past performance is not indicative of future performance. Any opinions and or recommendations expressed in this material are subject to change without notice and, Laverne and Banyan Tree are not under any obligation to update or keep current the information contained herein. References made to third parties are based on information believed to be reliable but are not guaranteed as being accurate.

Laverne and Banyan Tree and its respective officers may have an interest in the securities or derivatives of any entities referred to in this material. Laverne and Banyan Tree do and seek to do business with companies that are the subject of its research reports. The analyst(s) hereby certify that all the views expressed in this report accurately reflect their personal views about the subject investment theme and/or company securities.

Although every attempt has been made to verify the accuracy of the information contained in the document, liability for any errors or omissions (except any statutory liability which cannot be excluded) is specifically excluded by Laverne and Banyan Tree, its associates, officers, directors, employees, and agents.  Except for any liability which cannot be excluded, Laverne and Banyan Tree, its directors, employees and agents accept no liability or responsibility for any loss or damage of any kind, direct or indirect, arising out of the use of all or any part of this material.  Recipients of this document agree in advance that Laverne and Banyan Tree are not liable to recipients in any matters whatsoever otherwise; recipients should disregard, destroy or delete this document. All information is correct at the time of publication. Laverne and Banyan Tree do not guarantee reliability and accuracy of the material contained in this document and are not liable for any unintentional errors in the document.

The securities of any company(ies) mentioned in this document may not be eligible for sale in all jurisdictions or to all categories of investors. This document is provided to the recipient only and is not to be distributed to third parties without the prior consent of Laverne and Banyan Tree.

Categories
Global stocks Shares

Washington H. Soul Pattinson and Company Ltd (SOL) reported strong 1H22 results reflecting a strong uplift in profit

Stock market digital graph chart on LED display concept. A large display of daily stock market price and quotation. Indicator financial forex trade education background.

Investment Thesis

  • Trades on fair-value in terms of the valuation. 
  • The portfolio is well positioned and diversified, providing access to a range of asset classes across sectors, including equities, private equity, private credit and property. 
  • Solid investment philosophy/approach as investment strategies have delivered above market returns for over 5-yr, 10-yr, 15-yr and 20-yr timeframe. 
  • Strong management/investment team led by Rob Millner, with solid credentials and a strong track record of execution and active stewardship of capital. 
  • Strong track record of paying a consistent and increasing dividend for over 20 years.

Key Risks

  • Deterioration in performance in investments. 
  • Global and Australian economic conditions deteriorate. 
  • The investment Manager/analysts miss-calculate their bottom-up valuation of investments.
  • Reliance on the investment team and their expertise to outperform investment benchmarks. Hence key man risks and departure of key investment personnel, especially Rob Millner.

Key Highlights: Relative to the pcp and on a constant currency basis: 

  • Strong uplift in profit after tax of $343.7m, up +281% relative to the pcp of $90.2m. 
  • Net Cash Flow from Investments of $182.6m, was up +114% (or on a like for like basis, excluding the acquisition of Milton, was up 81%).
  • Pre-tax Net Asset Value per share up +3.4% for the period (outperformance of 8.6% against market). After tax Net Asset Value per share up +17.7% over first half (outperformance of 22.9% against market).
  • SOL completed its merger with Milton Corporation. 
  • The Board declared a fully franked interim Segment; EBITDA declined -21% amid higher employee costs reflecting expansion of the workforce and Covid-19 related cancelled/deferred cycles.
  • Completed merger with Milton Corporation.
  • Goodwill of $954m was created because of an increase in SOL share price between the date the transaction was announced to the market and the date control passed to SOL (5 October 2021).
  • 1H22 statutory profit was impacted by a one-off, noncash impairment of all the goodwill associated with the transaction.

Company Description

Washington H. Soul Pattinson and Company Ltd (ASX: SOL) holds a diversified portfolio of uncorrelated investments across listed equities, private equity, property and loans. It has a flexible mandate to generate returns by making long-term investment decisions and adjust the portfolio by changing the mix of investment classes over time. The Company is the second oldest publicly listed company on the ASX and has been successfully managed by the same family from the outset: Lewy Pattinson, Fred Pattinson, Jim Millner and current Chairman, Rob Millner.

DISCLAIMER for General Advice: (This document is for general advice only).

This document is provided by Laverne Securities Pty Ltd T/as Laverne Investing. Laverne Securities Pty Ltd, CAR 001269781 of Laverne Capital Pty Ltd AFSL No. 482937.

The material in this document may contain general advice or recommendations which, while believed to be accurate at the time of publication, are not appropriate for all persons or accounts. This document does not purport to contain all the information that a prospective investor may require.  The material contained in this document does not take into consideration an investor’s objectives, financial situation or needs. Before acting on the advice, investors should consider the appropriateness of the advice, having regard to the investor’s objectives, financial situation, and needs. The material contained in this document is for sales purposes. The material contained in this document is for information purposes only and is not an offer, solicitation or recommendation with respect to the subscription for, purchase or sale of securities or financial products and neither or anything in it shall form the basis of any contract or commitment. This document should not be regarded by recipients as a substitute for the exercise of their own judgment and recipients should seek independent advice.

The material in this document has been obtained from sources believed to be true but neither Laverne and Banyan Tree nor its associates make any recommendation or warranty concerning the accuracy or reliability or completeness of the information or the performance of the companies referred to in this document. Past performance is not indicative of future performance. Any opinions and or recommendations expressed in this material are subject to change without notice and, Laverne and Banyan Tree are not under any obligation to update or keep current the information contained herein. References made to third parties are based on information believed to be reliable but are not guaranteed as being accurate.

Laverne and Banyan Tree and its respective officers may have an interest in the securities or derivatives of any entities referred to in this material. Laverne and Banyan Tree do and seek to do business with companies that are the subject of its research reports. The analyst(s) hereby certify that all the views expressed in this report accurately reflect their personal views about the subject investment theme and/or company securities.

Although every attempt has been made to verify the accuracy of the information contained in the document, liability for any errors or omissions (except any statutory liability which cannot be excluded) is specifically excluded by Laverne and Banyan Tree, its associates, officers, directors, employees, and agents.  Except for any liability which cannot be excluded, Laverne and Banyan Tree, its directors, employees and agents accept no liability or responsibility for any loss or damage of any kind, direct or indirect, arising out of the use of all or any part of this material.  Recipients of this document agree in advance that Laverne and Banyan Tree are not liable to recipients in any matters whatsoever otherwise; recipients should disregard, destroy or delete this document. All information is correct at the time of publication. Laverne and Banyan Tree do not guarantee reliability and accuracy of the material contained in this document and are not liable for any unintentional errors in the document.

The securities of any company(ies) mentioned in this document may not be eligible for sale in all jurisdictions or to all categories of investors. This document is provided to the recipient only and is not to be distributed to third parties without the prior consent of Laverne and Banyan Tree.

Categories
Global stocks Shares

A2M delivered a solid FY22 result which was ahead of consensus expectations

Investment Thesis

  • Management appears to be working through the inventory issues which have impacted the Company in the recent past.
  • Potential to win market share in Australia and China.
  • Growing consumer demand for health and well-being globally.
  • Demand growth in China for premium infant formula products.
  • Expansion into new priority markets, aided by the capabilities of Fonterra.
  • US expansion provides new markets + opportunities.
  • Key patents provide a barrier to entry.
  • Takeover target – the Company was the subject of a takeover bid in 2015.

Key Risks

  • Management fails to meet its revised FY21 guidance. 
  • Chinese demand is underperforming market expectations. 
  • Disruption to A2 milk supply. 
  • Increased competition, including private labels & competitors developing products or branding that erode the differentiation of A2M branded products from other dairy products.
  • Expiration of A2M’s intellectual property rights may weaken or be infringed by competitors.  Withdrawal of A2M product from international markets due to market share loss or lack of market penetration.

Key Highlights

  • FY22 results highlights. Relative to the pcp: 
  • Group net revenue was up +19.8% YoY to $1,443.7m, driven by solid growth in IMF (up +11.9% YoY) and the inclusion of MVM. Excluding MVM, group revenue was up +11.2% YoY. The Company also made good progress on rebalancing inventory in the 2H22 vs 1H22. China & Other Asia revenue was up +24.5% YoY on the back of strong execution in China, strong China label IMF consumer demand, pricing benefits and positive movement in forex. 
  • Gross profit was up +30.2% to $663.5m, with % GM up +370 bps to 46.0% versus pcp given the cycling of stock write-downs in pcp, higher pricing, lower trade spends and favourable forex. Partially by higher raw materials and logistics costs. 
  • Strong top line growth and gross margin improvement drove FY22 EBITDA higher by +59% to $196.2m. EBITDA margin expanded by +330bps, driven by margin expansion in both ANZ (up +590bps) and China & Other Asia (up +700 bps). Marketing costs of $230.0m were up +36.3% YoY to support A2M’s China strategy execution. 
  • NPAT (including non-controlling interest) was up +42.3% YoY to $114.7m and EPS of 16.5cps was up +51.8%. 
  • Balance sheet is solid with a net cash position of $816.5m.
  • On-market share buyback. On the back of improving market conditions and strong operating performance, the Board announced a capital return of $150m via an on-market share buyback. It is expected to start at the end of September and be carried out over next 12-months.

Company Description

The a2 Milk Company Limited (A2M) sells a2 brand milk and related products. The company owns intellectual property that enables the identification of cattle for the production of A1 protein free milk products. It also sources and supplies a2 brand milk in Australia, the UK and the US, exports a2 brand milk to China, and distributes and markets a2 brand milk and a2 Platinum brand infant nutrition products in Australia, New Zealand, and China.

(Source: Banyantree)

DISCLAIMER for General Advice: (This document is for general advice only).

This document is provided by Laverne Securities Pty Ltd T/as Laverne Investing. Laverne Securities Pty Ltd, CAR 001269781 of Laverne Capital Pty Ltd AFSL No. 482937.

The material in this document may contain general advice or recommendations which, while believed to be accurate at the time of publication, are not appropriate for all persons or accounts. This document does not purport to contain all the information that a prospective investor may require.  The material contained in this document does not take into consideration an investor’s objectives, financial situation or needs. Before acting on the advice, investors should consider the appropriateness of the advice, having regard to the investor’s objectives, financial situation, and needs. The material contained in this document is for sales purposes. The material contained in this document is for information purposes only and is not an offer, solicitation or recommendation with respect to the subscription for, purchase or sale of securities or financial products and neither or anything in it shall form the basis of any contract or commitment. This document should not be regarded by recipients as a substitute for the exercise of their own judgment and recipients should seek independent advice.

The material in this document has been obtained from sources believed to be true but neither Laverne and Banyan Tree nor its associates make any recommendation or warranty concerning the accuracy or reliability or completeness of the information or the performance of the companies referred to in this document. Past performance is not indicative of future performance. Any opinions and or recommendations expressed in this material are subject to change without notice and, Laverne and Banyan Tree are not under any obligation to update or keep current the information contained herein. References made to third parties are based on information believed to be reliable but are not guaranteed as being accurate.

Laverne and Banyan Tree and its respective officers may have an interest in the securities or derivatives of any entities referred to in this material. Laverne and Banyan Tree do and seek to do business with companies that are the subject of its research reports. The analyst(s) hereby certify that all the views expressed in this report accurately reflect their personal views about the subject investment theme and/or company securities.

Although every attempt has been made to verify the accuracy of the information contained in the document, liability for any errors or omissions (except any statutory liability which cannot be excluded) is specifically excluded by Laverne and Banyan Tree, its associates, officers, directors, employees, and agents.  Except for any liability which cannot be excluded, Laverne and Banyan Tree, its directors, employees and agents accept no liability or responsibility for any loss or damage of any kind, direct or indirect, arising out of the use of all or any part of this material.  Recipients of this document agree in advance that Laverne and Banyan Tree are not liable to recipients in any matters whatsoever otherwise; recipients should disregard, destroy or delete this document. All information is correct at the time of publication. Laverne and Banyan Tree do not guarantee reliability and accuracy of the material contained in this document and are not liable for any unintentional errors in the document.

The securities of any company(ies) mentioned in this document may not be eligible for sale in all jurisdictions or to all categories of investors. This document is provided to the recipient only and is not to be distributed to third parties without the prior consent of Laverne and Banyan Tree.

Categories
Global stocks Shares

Williams-Sonoma has set its sights on expanding its total addressable market outside of furniture

Business Strategy & Outlook

Williams-Sonoma has carved out a solid position in the $750 billion global home category and the $80 billion U.S. business-to-business industry. It has historically launched most of its brands organically in underserved segments and its brand intangible asset has been the supporting factor in its top- and bottom-line growth. Its ability to drive repeat business relies on customer loyalty and smart marketing and merchandising and the firm has access to some of the best analytics in retail. This should help Williams-Sonoma outperform its competitors and grow its market share, aided by new category expansions. In recent years, Williams-Sonoma has set its sights on expanding its total addressable market outside of furniture and home furnishings, via B2B and marketplace efforts, categories with robust end markets that remain fragmented. These white-space business lines, along with faster growth from both franchise and the e-commerce channels (which accounted for 66% of 2021 sales) should help 

Williams-Sonoma reached $10 billion in sales in 2026. Furthermore, the aforementioned categories have the ability to deliver better operating margins than the historical brick-and-mortar business (which is on track to decrease its store base by 25% between 2020 and 2025), allowing mix to offer a natural lift to profitability. Such efforts, along with lower costs from an improved supply chain (when COVID-19 constraints subside), better distribution network (from direct sourcing and furniture delivery operations), as well as higher productivity of its store fleet (as underperforming locations close and older leases are renegotiated) should allow for operating margins that are consistently at a midteens rate. Despite a solid competitive edge, the company isn’t insulated from the proliferation of e-commerce peers such as no-moat Wayfair pushing harder into the home furnishing space, bounding upside potential. Even with robust competition in the category, narrow-moat Williams-Sonoma could deliver an average adjusted return on invested capital, including goodwill, averaging 30% over the forecast, well ahead of the 9% weighted average cost of capital estimate.

Financial Strengths

Williams-Sonoma is in fine financial health, with plenty of cash on hand, ending its third quarter with $113 million on its balance sheet. Given the strong free cash flow it has been able to generate, the firm will not have to tap the equity or credit markets for liquidity anytime soon, and there is currently no long-term debt outstanding, liberating excess cash flow for a return to shareholders. Over the past five fiscal years, the company has produced cumulative free cash flow of $3.4 billion. Williams Sonoma’s cash requirements are primarily for inventory, property, plant, and equipment, advertising and marketing, technology, share repurchases, and dividends, which will mostly be funded by cash generated from operations. Free cash flow to equity has averaged about 10% of revenue during the past five years, which is decent for a company that can produce somewhat volatile results that are closely tied to the performance of the housing market. The company resumed share repurchases in the fourth quarter of 2020, and the board authorized a $1.5 billion share buyback program in March 2022, which should facilitate continued buybacks ahead (in fiscal 2021 the company repurchased $899 million in shares, well ahead of any other year in the past decade). Williams-Sonoma has repurchased $841 million in shares in the first three quarters of fiscal 2022. Additionally, it pays a dividend of $0.78 per quarter, representing a payout that was raised 10% in March 2022, illustrating the board’s confidence in the strength of the underlying business. Over the next decade, the firm is to average around 8% EPS growth (increasing modestly faster than sales), bolstered by continued top-line growth, a favorable sales mix shift, and stringent cost controls. Williams Sonoma is positioned to earn an average of around $1 billion in free cash flow (cash from operations minus capital expenditures) over the next five years.

Bulls Say

  • Less discretionary categories such as cookware and small appliances offer some resilience amid macroeconomic cyclicality. Registries in categories such as wedding and baby offer a steady source of customers.
  • The firm opened company-owned stores abroad in Australia in 2013 and has since expanded to the U.K.International opportunities (owned and franchised) could provide location and sales growth and elevated brand awareness.
  • Around two thirds (or more) of sales has stemmed from the e-commerce channel in recent years, which helps minimize store expenses and maximize operating margins.

Company Description

With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.

(Source: Morningstar)

DISCLAIMER for General Advice: (This document is for general advice only).

This document is provided by Laverne Securities Pty Ltd T/as Laverne Investing. Laverne Securities Pty Ltd, CAR 001269781 of Laverne Capital Pty Ltd AFSL No. 482937.The material in this document may contain general advice or recommendations which, while believed to be accurate at the time of publication, are not appropriate for all persons or accounts. This document does not purport to contain all the information that a prospective investor may require.  The material contained in this document does not take into consideration an investor’s objectives, financial situation or needs. Before acting on the advice, investors should consider the appropriateness of the advice, having regard to the investor’s objectives, financial situation, and needs. The material contained in this document is for sales purposes. The material contained in this document is for information purposes only and is not an offer, solicitation or recommendation with respect to the subscription for, purchase or sale of securities or financial products and neither or anything in it shall form the basis of any contract or commitment. This document should not be regarded by recipients as a substitute for the exercise of their own judgment and recipients should seek independent advice. The material in this document has been obtained from sources believed to be true but neither Laverne and Banyan Tree nor its associates make any recommendation or warranty concerning the accuracy or reliability or completeness of the information or the performance of the companies referred to in this document. Past performance is not indicative of future performance. Any opinions and or recommendations expressed in this material are subject to change without notice and, Laverne and Banyan Tree are not under any obligation to update or keep current the information contained herein. References made to third parties are based on information believed to be reliable but are not guaranteed as being accurate.

Laverne and Banyan Tree and its respective officers may have an interest in the securities or derivatives of any entities referred to in this material. Laverne and Banyan Tree do and seek to do business with companies that are the subject of its research reports. The analyst(s) hereby certify that all the views expressed in this report accurately reflect their personal views about the subject investment theme and/or company securities.

Although every attempt has been made to verify the accuracy of the information contained in the document, liability for any errors or omissions (except any statutory liability which cannot be excluded) is specifically excluded by Laverne and Banyan Tree, its associates, officers, directors, employees, and agents.  Except for any liability which cannot be excluded, Laverne and Banyan Tree, its directors, employees and agents accept no liability or responsibility for any loss or damage of any kind, direct or indirect, arising out of the use of all or any part of this material.  Recipients of this document agree in advance that Laverne and Banyan Tree are not liable to recipients in any matters whatsoever otherwise; recipients should disregard, destroy or delete this document. All information is correct at the time of publication. Laverne and Banyan Tree do not guarantee reliability and accuracy of the material contained in this document and are not liable for any unintentional errors in the document.

The securities of any company(ies) mentioned in this document may not be eligible for sale in all jurisdictions or to all categories of investors. This document is provided to the recipient only and is not to be distributed to third parties without the prior consent of Laverne and Banyan Tree.

Categories
Global stocks

Huntington returned to the acquisition front in a big way in 2016 with the purchase of FirstMerit

Over the shoulder view of and stock broker trading online while accepting orders by phone. Multiple computer screens ful of charts and data analyses in background.

Business Strategy & Outlook

Huntington Bancshares did not fare well in the aftermath of the financial crisis, largely because of the poorly timed acquisition of Sky Financial in 2007. Although it seemed a reasonable combination at the time with significant footprint overlap, the potential for considerable synergies turned into massive losses due to the subprime mortgage business and bad commercial loans. Under its new leader, Stephen Steinour, Huntington embarked on a strategy shift in 2010 that focused on delivering strong customer service to middle-market businesses and retail clients. The bank also took steps to improve its internal credit procedures and shore up its balance sheet. This strategy has been successful. Commercial and consumer relationships have grown, Huntington has been successful at expanding relationships across multiple product lines, and overall fee income has improved. In 2016, the bank stated that 47% of its commercial clients used four or more of its products or services, up from 22% in 2010, while 52% of retail customers used at least six or more services, up from 43% in 2013. Huntington returned to the acquisition front in a big way in 2016 with the purchase of FirstMerit. This added much-needed scale and efficiency while improving market share. After cutting over 40% of FirstMerit’s original cost base, Huntington sold its more expensive product set in new and underpenetrated markets. Growth in home lending in Chicago and growth from the RV/boat financing unit have been very strong, indicating that the merger worked. Meanwhile, Huntington’s auto financing franchise remains strong as ever. 

Since FirstMerit, Huntington has completed several bolt-on acquisitions, including HSE in 2018 and Capstone Partners in 2022 to help further build out their capital markets unit. Huntington also completed another sizable banking acquisition in 2021 with TCF Financial, in a classic cost-saving, market-overlap play. Beginning to get a true feel for more normalized financials following the acquisition. The initial impression is that the bank may struggle to reach its goal of 17%-plus returns on tangible common equity through the cycle.

Financial Strengths

Huntington is in solid financial health. The bank has been generating profits since 2010, with returns on tangible equity handily exceeding its 9% cost of capital. Huntington reported a common equity Tier 1 capital ratio of 9.3% as of September 2022, and given the bank’s moderate to low appetite for risk, this seems very reasonable to us

Bulls Say

  • A strong economy and higher rates are all positives for the banking sector and should propel revenue and profitability even higher. 
  • Huntington’s recent acquisitions have improved the bank’s scale and share, and more revenue growth could be right around the corner. 
  • Huntington has taken advantage of new markets and product sets from its acquisitions, growing fee income and taking some share along the way. This could continue, potentially allowing Huntington to grow revenue faster than peers.

Company Description

Huntington Bancshares is a regional bank holding company headquartered in Columbus, Ohio. The bank has a network of branches and ATMs across eight Midwestern states. Founded in 1866, Huntington National Bank and its affiliates provide consumer, small-business, commercial, treasury management, wealth management, brokerage, trust, and insurance services. Huntington also provides auto dealer, equipment finance, national settlement, and capital market services that extend beyond its core states.

(Source: Morningstar)

DISCLAIMER for General Advice: (This document is for general advice only).

This document is provided by Laverne Securities Pty Ltd T/as Laverne Investing. Laverne Securities Pty Ltd, CAR 001269781 of Laverne Capital Pty Ltd AFSL No. 482937.The material in this document may contain general advice or recommendations which, while believed to be accurate at the time of publication, are not appropriate for all persons or accounts. This document does not purport to contain all the information that a prospective investor may require.  The material contained in this document does not take into consideration an investor’s objectives, financial situation or needs. Before acting on the advice, investors should consider the appropriateness of the advice, having regard to the investor’s objectives, financial situation, and needs. The material contained in this document is for sales purposes. The material contained in this document is for information purposes only and is not an offer, solicitation or recommendation with respect to the subscription for, purchase or sale of securities or financial products and neither or anything in it shall form the basis of any contract or commitment. This document should not be regarded by recipients as a substitute for the exercise of their own judgment and recipients should seek independent advice. The material in this document has been obtained from sources believed to be true but neither Laverne and Banyan Tree nor its associates make any recommendation or warranty concerning the accuracy or reliability or completeness of the information or the performance of the companies referred to in this document. Past performance is not indicative of future performance. Any opinions and or recommendations expressed in this material are subject to change without notice and, Laverne and Banyan Tree are not under any obligation to update or keep current the information contained herein. References made to third parties are based on information believed to be reliable but are not guaranteed as being accurate.

Laverne and Banyan Tree and its respective officers may have an interest in the securities or derivatives of any entities referred to in this material. Laverne and Banyan Tree do and seek to do business with companies that are the subject of its research reports. The analyst(s) hereby certify that all the views expressed in this report accurately reflect their personal views about the subject investment theme and/or company securities.

Although every attempt has been made to verify the accuracy of the information contained in the document, liability for any errors or omissions (except any statutory liability which cannot be excluded) is specifically excluded by Laverne and Banyan Tree, its associates, officers, directors, employees, and agents.  Except for any liability which cannot be excluded, Laverne and Banyan Tree, its directors, employees and agents accept no liability or responsibility for any loss or damage of any kind, direct or indirect, arising out of the use of all or any part of this material.  Recipients of this document agree in advance that Laverne and Banyan Tree are not liable to recipients in any matters whatsoever otherwise; recipients should disregard, destroy or delete this document. All information is correct at the time of publication. Laverne and Banyan Tree do not guarantee reliability and accuracy of the material contained in this document and are not liable for any unintentional errors in the document.

The securities of any company(ies) mentioned in this document may not be eligible for sale in all jurisdictions or to all categories of investors. This document is provided to the recipient only and is not to be distributed to third parties without the prior consent of Laverne and Banyan Tree.

Categories
Global stocks

Hub has constructed intermodal and truck brokerage networks of sufficient scale to be attractive to customers

Graphic of investment stock market data analysis business

Business Strategy & Outlook

Hub Group is the second-largest intermodal marketing company and also ranks among the 20 largest asset-light truck brokers in terms of gross revenue. In its flagship intermodal division, Hub contracts with the Class I railroads for the line-haul movement of its owned containers. It operates the second-largest fleet in the industry, with exclusive access to more than 30,000 containers, and enjoys an approximate 10% market share. By gross revenue, J.B. Hunt is the largest intermodal marketing company, followed by Hub and the intermodal divisions of STG Logistics, Schneider National and Knight Swift. Hub has constructed intermodal and truck brokerage networks of sufficient scale to be attractive to customers (shippers) and suppliers, both of which benefit from using a larger intermediary. 

Sophisticated IT systems and market know-how enable customers to outsource intermodal shipping to an expert specialist, while Hub’s large volume of loads and significant control of containers make it an attractive customer to the Class I railroads. The company’s primary rail carriers are Norfolk Southern in the East and Union Pacific in the West. Rates in the competing truckload market corrected in 2019, pressuring intermodal value proposition relative to trucking, and initial pandemic disruption pressured container volume into early 2020. However, truckload capacity tightened drastically by mid-2020 (remaining scarce through most of 2022), while contract pricing soared across all modes and underlying intermodal demand jumped on heavy retail shipper restocking (intermodal cargo is mostly consumer goods). The onset of rail service shortfalls in second-half 2021 has throttled Hub’s container volume growth despite otherwise positive freight demand, but the firm is working diligently with the railroads and customers to minimize the issue. A growth across Hub’s intermodal can be seen, truck brokerage and dedicated operations will take a breather in 2023. That said, for intermodal 2.5%-3.0% normalized U.S. retail sales growth and conversion trends to support 3.0%-3.5% industry container volume expansion longer-term, with 2.0%-2.5% pricing gains on average.

Financial Strengths

Hub Group’s balance sheet is healthy, and the firm is not overly leveraged. At the end of 2021, Hub held a manageable amount of debt, which is normally used to help finance equipment purchases (especially intermodal containers) as well as tuck-in acquisitions like the 2020 Nonstop Delivery deal. Total debt came in near $275 million in 2021. Debt/EBITDA stood at less than 1 times in 2021, versus 1 time in 2020 and a five-year average near 1.3 times. The firm held roughly $160 million in cash at year-end 2021 versus an approximate $125 million in 2020. Historically, Hub’s model generated decent free cash flow in years when it wasn’t acquiring intermodal containers. Overall, free cash flow averaged 2.5% of gross revenue over the past five years, with capital expenditures approximating 3% of sales. Capital expenditures will likely come in near 5% of sales in 2022 due in part to investment in additional intermodal containers to capitalize on growth opportunities. The 2017 acquisition of Estenson, which provides asset-based dedicated trucking services, incrementally moved Hub into the capital-intensive truckload shipping business, and the operation originally required meaningful investment in tractors to support fleet growth. Most of the firm’s logistics-segment operations, including last mile and truck brokerage, are asset light by nature.

Bulls Say

  • Contract pricing across the intermodal and truckload shipping sectors is likely to normalize in 2023 as capacity constraints diminish. 
  • Because of high inventory levels, retail customers’ trailer detention levels are abnormally high, contributing to network inefficiencies across Hunt’s.
  • In Hub’s core intermodal division, transportation costs and customer satisfaction depend heavily on the performance of partner Class I railroads, which have been grappling with labor-related network headwinds.

Company Description

Hub Group ranks among the largest asset light providers of rail intermodal service. Roughly 60% of revenue comes from Hub’s intermodal and transportation solutions division. ITS includes its flagship intermodal operations, which use the Class I rail carriers for the underlying line-haul movement of containers, as well as its dedicated truckload unit. Asset light truckload and LTL brokerage makes up around 20%. The remaining 20% reflects Hub’s logistics division, which provides outsourced transportation management, warehousing and fulfillment, and final mile delivery. Hub is somewhat acquisitive in that it often makes tuck-in acquisitions which expand its brokerage, logistics, and dedicated truckload offerings.

(Source: Morningstar)

DISCLAIMER for General Advice: (This document is for general advice only).

This document is provided by Laverne Securities Pty Ltd T/as Laverne Investing. Laverne Securities Pty Ltd, CAR 001269781 of Laverne Capital Pty Ltd AFSL No. 482937.The material in this document may contain general advice or recommendations which, while believed to be accurate at the time of publication, are not appropriate for all persons or accounts. This document does not purport to contain all the information that a prospective investor may require.  The material contained in this document does not take into consideration an investor’s objectives, financial situation or needs. Before acting on the advice, investors should consider the appropriateness of the advice, having regard to the investor’s objectives, financial situation, and needs. The material contained in this document is for sales purposes. The material contained in this document is for information purposes only and is not an offer, solicitation or recommendation with respect to the subscription for, purchase or sale of securities or financial products and neither or anything in it shall form the basis of any contract or commitment. This document should not be regarded by recipients as a substitute for the exercise of their own judgment and recipients should seek independent advice. The material in this document has been obtained from sources believed to be true but neither Laverne and Banyan Tree nor its associates make any recommendation or warranty concerning the accuracy or reliability or completeness of the information or the performance of the companies referred to in this document. Past performance is not indicative of future performance. Any opinions and or recommendations expressed in this material are subject to change without notice and, Laverne and Banyan Tree are not under any obligation to update or keep current the information contained herein. References made to third parties are based on information believed to be reliable but are not guaranteed as being accurate.

Laverne and Banyan Tree and its respective officers may have an interest in the securities or derivatives of any entities referred to in this material. Laverne and Banyan Tree do and seek to do business with companies that are the subject of its research reports. The analyst(s) hereby certify that all the views expressed in this report accurately reflect their personal views about the subject investment theme and/or company securities.

Although every attempt has been made to verify the accuracy of the information contained in the document, liability for any errors or omissions (except any statutory liability which cannot be excluded) is specifically excluded by Laverne and Banyan Tree, its associates, officers, directors, employees, and agents.  Except for any liability which cannot be excluded, Laverne and Banyan Tree, its directors, employees and agents accept no liability or responsibility for any loss or damage of any kind, direct or indirect, arising out of the use of all or any part of this material.  Recipients of this document agree in advance that Laverne and Banyan Tree are not liable to recipients in any matters whatsoever otherwise; recipients should disregard, destroy or delete this document. All information is correct at the time of publication. Laverne and Banyan Tree do not guarantee reliability and accuracy of the material contained in this document and are not liable for any unintentional errors in the document.

The securities of any company(ies) mentioned in this document may not be eligible for sale in all jurisdictions or to all categories of investors. This document is provided to the recipient only and is not to be distributed to third parties without the prior consent of Laverne and Banyan Tree.

Categories
Global stocks

MYX’s bottom line was severely impacted by investments for US launch of NEXTSTELLIS, noncash NEXTSTELLIS deferred consideration reassessment

Investment Thesis

  • Any stabilization (competition or price) in the generic segment will be viewed as a positive.
  • New product launches and healthy development pipeline.
  • While generic brands are going through a tough trading environment at the moment, the long-term outlook remains positive given consumers and regulators need a healthy generics market to keep the price of medication down.
  • Positioning the product portfolio to higher margin products.
  • Potential industry consolidation on lower growth outlook.
  • Leveraged to a falling AUD/USD.

Key Risks

  • Intense competition from new products. 
  • Lower demand. 
  • New product launches fail to deliver the growth expected by the market. 
  • Regulatory changes. 
  • Litigation. 
  • Adverse currency movement.

Key Highlights: Relative to the pcp and on a constant currency basis: 

  • Revenues increased +6% to $424.8m, with Branded Products up +40%, International up +27%, Metrics Contract Services up +11% and Portfolio Products flat as strong performance in Dermatology benefiting from 12 product launches offset by continued erosion and underperformance of retail generics.
  • Operating expenses increased +43% to $157.5m, due to the US launch of NEXTSTELLIS.
  •  Reported EBITDA increased +32% to $87.4m, affected by the non-cash NEXTSTELLIS deferred consideration reassessment, stock write-downs and returns on discontinued, unprofitable retail generic products, transaction and restructuring costs. Underlying EBITDA of $45.7m, declined -28% and underlying EBITDA excluding NEXTSTELLIS increased +24% to $89.7m. 
  • Reported net loss after tax widened +26% to $263.3m, driven by intangible asset impairments and deferred tax assets write-downs. 
  • FCF was an outflow of $35.7m, due to earnout payments, primarily impacted by increase in working capital to support the launch of NEXTSTELLIS and the new dermatology products. 
  • Net debt of $317m increased +27%, however, the company remained compliant with all bank covenants, with interest cover 5.1x (covenant >3x), shareholders’ funds of $562m (covenant >$400m) and liquidity (cash and undrawn debt) of $122m (covenant >$65m).

Company Description

Mayne Pharma Group (MYX) Mayne Pharma is a specialty pharmaceutical company focused on applying its drug delivery expertise to commercialize branded and generic pharmaceuticals. Mayne Pharma provides contract development and manufacturing services to more than 100 clients worldwide. Mayne Pharma has an extensive portfolio of branded and generic drugs in multiple therapeutic areas, including women’s health, oncology, dermatology and cardiology.

DISCLAIMER for General Advice: (This document is for general advice only).

This document is provided by Laverne Securities Pty Ltd T/as Laverne Investing. Laverne Securities Pty Ltd, CAR 001269781 of Laverne Capital Pty Ltd AFSL No. 482937.

The material in this document may contain general advice or recommendations which, while believed to be accurate at the time of publication, are not appropriate for all persons or accounts. This document does not purport to contain all the information that a prospective investor may require.  The material contained in this document does not take into consideration an investor’s objectives, financial situation or needs. Before acting on the advice, investors should consider the appropriateness of the advice, having regard to the investor’s objectives, financial situation, and needs. The material contained in this document is for sales purposes. The material contained in this document is for information purposes only and is not an offer, solicitation or recommendation with respect to the subscription for, purchase or sale of securities or financial products and neither or anything in it shall form the basis of any contract or commitment. This document should not be regarded by recipients as a substitute for the exercise of their own judgment and recipients should seek independent advice.

The material in this document has been obtained from sources believed to be true but neither Laverne and Banyan Tree nor its associates make any recommendation or warranty concerning the accuracy or reliability or completeness of the information or the performance of the companies referred to in this document. Past performance is not indicative of future performance. Any opinions and or recommendations expressed in this material are subject to change without notice and, Laverne and Banyan Tree are not under any obligation to update or keep current the information contained herein. References made to third parties are based on information believed to be reliable but are not guaranteed as being accurate.

Laverne and Banyan Tree and its respective officers may have an interest in the securities or derivatives of any entities referred to in this material. Laverne and Banyan Tree do and seek to do business with companies that are the subject of its research reports. The analyst(s) hereby certify that all the views expressed in this report accurately reflect their personal views about the subject investment theme and/or company securities.

Although every attempt has been made to verify the accuracy of the information contained in the document, liability for any errors or omissions (except any statutory liability which cannot be excluded) is specifically excluded by Laverne and Banyan Tree, its associates, officers, directors, employees, and agents.  Except for any liability which cannot be excluded, Laverne and Banyan Tree, its directors, employees and agents accept no liability or responsibility for any loss or damage of any kind, direct or indirect, arising out of the use of all or any part of this material.  Recipients of this document agree in advance that Laverne and Banyan Tree are not liable to recipients in any matters whatsoever otherwise; recipients should disregard, destroy or delete this document. All information is correct at the time of publication. Laverne and Banyan Tree do not guarantee reliability and accuracy of the material contained in this document and are not liable for any unintentional errors in the document.

The securities of any company(ies) mentioned in this document may not be eligible for sale in all jurisdictions or to all categories of investors. This document is provided to the recipient only and is not to be distributed to third parties without the prior consent of Laverne and Banyan Tree.

Categories
Global stocks

Sonic benefits from cost efficiencies by maximizing throughput through its network of laboratories and collection centers

Business Strategy & Outlook

Sonic’s “medical leadership” model recognizes the importance of the referring doctor as the company seeks to differentiate itself on service levels. Success in the model is evidenced by organic growth consistently tracking ahead of the market, suggesting market share gains. In an industry where absolute volumes are an important component in achieving greater cost advantage, organic growth supplemented by appropriate acquisitions continues to add value for shareholders. Sonic’s organic volume growth in its core laboratories segment has typically ranged between 3% and 4%. The volume growth is underpinned by population growth, aging demographics in developed markets, higher incidence of diseases, and wider adoption of preventative diagnostics to manage healthcare costs. In addition, the number of tests available is expanding. Increasing complexity of tests, such as veterinary and gene-based testing, is also resulting in average fee price increases. 

Laboratory medicine, or pathology, has a high fixed cost of operation and thus benefits from volume growth to drive lower cost-per-test outcomes. Sonic benefits from cost efficiencies by maximizing throughput through its network of laboratories and collection centers. Higher testing volumes result in a lower cost per test as labor, equipment, leases, transportation, and overhead costs are all leveraged. The company has historically been highly acquisitive, particularly overseas. Synergies from procurement and integrating IT are relatively easy to capture, and given its cost advantage, Sonic is well placed to boost its organic revenue with bolt-on acquisitions. The U.S. and Germany are singled out as the most likely sources of acquisitions given their fragmented markets. In addition to acquisitions, Sonic is sourcing more volumes to put through its laboratories from joint ventures with hospitals in the U.S., whose in-house laboratories are typically subscale and would operate at higher costs. Operating capacity within Sonic’s existing laboratories is highly flexible by adjusting operating hours.

Financial Strengths

Sonic is in a strong financial position. Free cash flow conversion of earnings prior to acquisition spend has averaged 99% over the last 10 years and has allowed Sonic to quickly repay the debt funding its acquisitions. In June 2022, Sonic reported AUD 797 million in net debt representing net debt/EBITDA of only 0.3 times, below the 2.0 to 2.7 times range targeted by management, and well below the 3.5 times covenant. A similarly strong cash conversion can be seen, and in the absence of major acquisitions, the company will be in a net cash position for most of the 10-year forecast period. The high cash conversion affords Sonic a generous dividend payout ratio, which is to be consistent with the historical average of approximately 75% of earnings. Sonic also has a progressive dividend policy which is communicated as a minimum of an equal dividend per share to the prior year.

Bulls Say

  • Sonic has a leading market position in most of its geographies and as a result benefits from a cost advantage derived from scale. 
  • On top of the base level of COVID-19 testing that is likely to continue, demographic factors, and the focus on value-based healthcare support global volume growth in preventative diagnostics. 
  • Advances in technology and personalized medicine are increasing the number of complex and gene-based tests available to patients which are typically higher-margin.

Company Description

Sonic Healthcare is a global pathology provider. It is the largest private operator in Australia, Germany, Switzerland and the U.K., the second largest in Belgium and New Zealand and the third largest in the U.S. In addition to pathology, which contributes roughly 85% of group revenue, Sonic is the second largest player in diagnostic imaging in Australia and the largest operator of medical centers in Australia. The company typically earns about 40% of group revenue in Australia and New Zealand, 25% in the U.S. and 35% in Europe.

(Source: Morningstar)

DISCLAIMER for General Advice: (This document is for general advice only).

This document is provided by Laverne Securities Pty Ltd T/as Laverne Investing. Laverne Securities Pty Ltd, CAR 001269781 of Laverne Capital Pty Ltd AFSL No. 482937.The material in this document may contain general advice or recommendations which, while believed to be accurate at the time of publication, are not appropriate for all persons or accounts. This document does not purport to contain all the information that a prospective investor may require.  The material contained in this document does not take into consideration an investor’s objectives, financial situation or needs. Before acting on the advice, investors should consider the appropriateness of the advice, having regard to the investor’s objectives, financial situation, and needs. The material contained in this document is for sales purposes. The material contained in this document is for information purposes only and is not an offer, solicitation or recommendation with respect to the subscription for, purchase or sale of securities or financial products and neither or anything in it shall form the basis of any contract or commitment. This document should not be regarded by recipients as a substitute for the exercise of their own judgment and recipients should seek independent advice. The material in this document has been obtained from sources believed to be true but neither Laverne and Banyan Tree nor its associates make any recommendation or warranty concerning the accuracy or reliability or completeness of the information or the performance of the companies referred to in this document. Past performance is not indicative of future performance. Any opinions and or recommendations expressed in this material are subject to change without notice and, Laverne and Banyan Tree are not under any obligation to update or keep current the information contained herein. References made to third parties are based on information believed to be reliable but are not guaranteed as being accurate.

Laverne and Banyan Tree and its respective officers may have an interest in the securities or derivatives of any entities referred to in this material. Laverne and Banyan Tree do and seek to do business with companies that are the subject of its research reports. The analyst(s) hereby certify that all the views expressed in this report accurately reflect their personal views about the subject investment theme and/or company securities.

Although every attempt has been made to verify the accuracy of the information contained in the document, liability for any errors or omissions (except any statutory liability which cannot be excluded) is specifically excluded by Laverne and Banyan Tree, its associates, officers, directors, employees, and agents.  Except for any liability which cannot be excluded, Laverne and Banyan Tree, its directors, employees and agents accept no liability or responsibility for any loss or damage of any kind, direct or indirect, arising out of the use of all or any part of this material.  Recipients of this document agree in advance that Laverne and Banyan Tree are not liable to recipients in any matters whatsoever otherwise; recipients should disregard, destroy or delete this document. All information is correct at the time of publication. Laverne and Banyan Tree do not guarantee reliability and accuracy of the material contained in this document and are not liable for any unintentional errors in the document.

The securities of any company(ies) mentioned in this document may not be eligible for sale in all jurisdictions or to all categories of investors. This document is provided to the recipient only and is not to be distributed to third parties without the prior consent of Laverne and Banyan Tree.

Categories
Global stocks Shares

Gilden has approximately 80% market share in printwear basics and acquisitions have made it a stronger player in fashion basics

Business Strategy & Outlook

Gildan Activewear lacks a moat, which has put it in a difficult position as it navigates disruption from the coronavirus pandemic and inflation. While Gildan began a private-label men’s underwear contract with wide-moat Walmart in 2019, this product has largely replaced Gildan-branded underwear and only partially offsets losses in other areas. Narrow-moat Hanesbrands and Fruit of the Loom have stronger innerwear brands, allowing them to hold significant shelf space at Walmart, no-moat Target, and other critical retailers. Mass retailers reportedly account for more than 60% of total underwear sales in the United States. Gildan has purchased a few notable brands, including Gold Toe (socks) and American Apparel (inexpensive fashion/printwear), having invested about $500 million in acquisitions since 2014. The company, though, no longer reports branded apparel as a separate business segment and recorded an impairment to goodwill related to its hosiery in 2020. It acknowledges market share losses to private-label brands, especially in socks, and its total yearly hosiery and underwear sales declined 21% between 2017 and 2021. 

There is a possibility that Gildan may end some of its hosiery programs to concentrate on its private-label business. Gildan’s success in printwear to its investments in the category and its cost-efficient production model. The firm has approximately 80% market share in printwear basics and acquisitions have made it a stronger player in fashion basics. Gildan’s printwear benefits from its strong supply chain as most of its clothing is manufactured in company-owned factories in low-wage, developing countries. Moreover, Gildan, unlike rivals, owns yarn-spinning factories in the U.S. that may improve its efficiency. In 2021, it bolstered its U.S. production with the acquisition of Frontier Yarns for about $170 million. Gildan’s investments have lowered its production costs, a permanent cost advantage hasn’t been created as its processes can be replicated by competitors and cost savings may be lost to lower prices.

Financial Strengths

In a move, Gildan cut spending to conserve cash during the COVID-19 crisis in 2020. Specifically, the firm lowered selling, general, and administrative expenses by 20%, suspended its dividends and share repurchases, and reduced its capital expenditures. However, as its results and finances improved in 2021, it stepped up cash usage, with capital expenditures of $127 million (4.4% of sales), about $250 million in share repurchases, and $90 million in dividend payments. Capital expenditures will rise to 6%-7% of sales over the next three years due to building projects and efficiency investments. Over the next decade, annual average repurchases of about $330 million and an annual average dividend payout ratio of 23%. Gildan’s total liquidity is solid. As of the end of September 2022, the firm had $920 million in debt, but also $69 million in cash and $680 million available on its revolving credit facility. Gildan will generate about $227 million in free cash flow to equity in 2022, more than enough to cover its obligations. Gildan renegotiated its debt covenants in June 2020 to avoid a possible violation. The firm closed 2019 with net debt/adjusted EBITDA of about 1.4 times, but this increased to 3.0 times at the end of 2020 because of the increased debt and a 70% drop in adjusted EBITDA for the year. However, its net debt/adjusted EBITDA fell to 0.6 times at the end of 2021 on debt reduction and higher EBITDA.

Bulls Say

  • Gildan has dominant market share in printwear basics and has invested in a low-cost production and distribution process to maintain its position. This business is recovering from the severe impact of the pandemic.
  • In 2019, Gildan won a contract with Walmart to supply men’s underwear for its in-house brand called George. While a blow to its branded business, the deal increased Gildan’s shelf space in the category.
  • Gildan’s Back to Basics efficiency strategy should allow it to hold operating margins around 18%, an improvement from prepandemic levels of about 15%.

Company Description

Gildan is a vertically-integrated designer and manufacturer of basic apparel, including T-shirts, underwear, socks, and hosiery. Its primary market is the sale of blank T-shirts and other apparel to wholesalers, major clothing brands, and printers (printwear). Gildan also sells branded clothing through retail and direct-to-consumer channels. Brands include Gildan, American Apparel, Comfort Colors, and Gold Toe. Gildan produces most of its clothing at factories in Latin America. The Montreal-based company generates most of its sales in the U.S. and was incorporated in 1984.

(Source: Morningstar)

DISCLAIMER for General Advice: (This document is for general advice only).

This document is provided by Laverne Securities Pty Ltd T/as Laverne Investing. Laverne Securities Pty Ltd, CAR 001269781 of Laverne Capital Pty Ltd AFSL No. 482937.The material in this document may contain general advice or recommendations which, while believed to be accurate at the time of publication, are not appropriate for all persons or accounts. This document does not purport to contain all the information that a prospective investor may require.  The material contained in this document does not take into consideration an investor’s objectives, financial situation or needs. Before acting on the advice, investors should consider the appropriateness of the advice, having regard to the investor’s objectives, financial situation, and needs. The material contained in this document is for sales purposes. The material contained in this document is for information purposes only and is not an offer, solicitation or recommendation with respect to the subscription for, purchase or sale of securities or financial products and neither or anything in it shall form the basis of any contract or commitment. This document should not be regarded by recipients as a substitute for the exercise of their own judgment and recipients should seek independent advice. The material in this document has been obtained from sources believed to be true but neither Laverne and Banyan Tree nor its associates make any recommendation or warranty concerning the accuracy or reliability or completeness of the information or the performance of the companies referred to in this document. Past performance is not indicative of future performance. Any opinions and or recommendations expressed in this material are subject to change without notice and, Laverne and Banyan Tree are not under any obligation to update or keep current the information contained herein. References made to third parties are based on information believed to be reliable but are not guaranteed as being accurate.

Laverne and Banyan Tree and its respective officers may have an interest in the securities or derivatives of any entities referred to in this material. Laverne and Banyan Tree do and seek to do business with companies that are the subject of its research reports. The analyst(s) hereby certify that all the views expressed in this report accurately reflect their personal views about the subject investment theme and/or company securities.

Although every attempt has been made to verify the accuracy of the information contained in the document, liability for any errors or omissions (except any statutory liability which cannot be excluded) is specifically excluded by Laverne and Banyan Tree, its associates, officers, directors, employees, and agents.  Except for any liability which cannot be excluded, Laverne and Banyan Tree, its directors, employees and agents accept no liability or responsibility for any loss or damage of any kind, direct or indirect, arising out of the use of all or any part of this material.  Recipients of this document agree in advance that Laverne and Banyan Tree are not liable to recipients in any matters whatsoever otherwise; recipients should disregard, destroy or delete this document. All information is correct at the time of publication. Laverne and Banyan Tree do not guarantee reliability and accuracy of the material contained in this document and are not liable for any unintentional errors in the document.

The securities of any company(ies) mentioned in this document may not be eligible for sale in all jurisdictions or to all categories of investors. This document is provided to the recipient only and is not to be distributed to third parties without the prior consent of Laverne and Banyan Tree.

Categories
Global stocks

Nufarm’s primary competitive strengths are marketing scale, dominant position in the Australian market, formulation expertise, and marketing skills

Business Strategy & Outlook

Nufarm is a major producer of crop-protection products including herbicides, fungicides, and pesticides, selling into all major world markets. The company is leveraged to growing demand for crops for biofuels, and food from rapidly industrializing markets such as China and India. Growth should come from astute brand and offshore business investments and from a customer service-focused strategy. However, the global crop-protection markets are competitive and earnings are cyclical, given a reliance on seasonal conditions. Sumitomo Chemical’s investment in Nufarm endorses the quality of its global distribution. Collaboration broadens product portfolios and adds distribution in Asia. Continued growth in food demand in industrializing nations should underwrite long-term earnings growth. Nufarm’s primary competitive strengths are marketing scale, dominant position in the Australian market, formulation expertise, and skills in marketing post-patent crop-protection products. Global expansion in recent years reduced dependency on the domestic market. The company’s dominance in Australia has become less certain, with glyphosate pricing coming under considerable pressure. Due to the competitive nature of its markets, lack of pricing power and exposure to cyclical agricultural demand, Nufarm doesn’t possess an economic moat. Returns on invested capital have historically failed to meet the cost of capital.

In addition to its crop-protection business, Nufarm has a seed technologies business. With this, it aims to broaden its portfolio of products, all of which are targeted to improve agricultural yields. Nufarm has a growing presence in North America and Europe. Sound sales momentum has been evident in North America and Europe. Several Chinese companies have previously expressed interest in acquiring Nufarm, but withdrew either because of too high a price demanded by the board, or because of reduced availability of debt. In 2010, Japanese company Sumitomo Chemical bought 20% of Nufarm, subsequently increasing its stake to 23% before diluting to 16% and then selling out completely in 2022.

Financial Strengths

Nufarm’s balance sheet is in great shape. In early April 2020, the company received AUD 1.2 billion net sale proceeds from major shareholder Sumitomo, for the sale of its South American crop protection and seed treatment operations in Brazil, Argentina, Colombia, and Chile. This significantly bolstered the finances at a very fortuitous time, coming mid coronavirus. Prior to this in January 2020, group net debt had stood at a whopping AUD 1.6 billion. Nufarm’s under-leveraged balance sheet remains a strength. At Sept. 30, 2022, net debt stood at a modest AUD 204 million excluding leases, leverage of just 9% and annualized net debt/EBITDA of 0.5 is very comfortable. Leverage is well below management’s net debt/EBITDA target range of 1.5 to 2.0. Nufarm is to be unleveraged within a year all else being equal. It would be wise for the company to remain modestly leveraged at most, given vagaries of the weather, earnings seasonality, and new product ramp-up requirements.

Bulls Say

  • Nufarm benefits from potential strength in soft commodities markets.
  • Nufarm has well-established distribution platforms in most major global agricultural markets.
  • Product and geographic diversification helps reduce earnings volatility.

Company Description

Nufarm Limited is a global crop-protection company that develops, manufactures, and sells a range of crop-protection products, including herbicides, insecticides, and fungicides. Nufarm sells its products in most of the world’s major agricultural regions, and operates primarily in the off-patent segment of the crop-protection market. Nufarm operates along two business lines: crop protection and seed technologies.

(Source: Morningstar)

DISCLAIMER for General Advice: (This document is for general advice only).

This document is provided by Laverne Securities Pty Ltd T/as Laverne Investing. Laverne Securities Pty Ltd, CAR 001269781 of Laverne Capital Pty Ltd AFSL No. 482937.The material in this document may contain general advice or recommendations which, while believed to be accurate at the time of publication, are not appropriate for all persons or accounts. This document does not purport to contain all the information that a prospective investor may require.  The material contained in this document does not take into consideration an investor’s objectives, financial situation or needs. Before acting on the advice, investors should consider the appropriateness of the advice, having regard to the investor’s objectives, financial situation, and needs. The material contained in this document is for sales purposes. The material contained in this document is for information purposes only and is not an offer, solicitation or recommendation with respect to the subscription for, purchase or sale of securities or financial products and neither or anything in it shall form the basis of any contract or commitment. This document should not be regarded by recipients as a substitute for the exercise of their own judgment and recipients should seek independent advice. The material in this document has been obtained from sources believed to be true but neither Laverne and Banyan Tree nor its associates make any recommendation or warranty concerning the accuracy or reliability or completeness of the information or the performance of the companies referred to in this document. Past performance is not indicative of future performance. Any opinions and or recommendations expressed in this material are subject to change without notice and, Laverne and Banyan Tree are not under any obligation to update or keep current the information contained herein. References made to third parties are based on information believed to be reliable but are not guaranteed as being accurate.

Laverne and Banyan Tree and its respective officers may have an interest in the securities or derivatives of any entities referred to in this material. Laverne and Banyan Tree do and seek to do business with companies that are the subject of its research reports. The analyst(s) hereby certify that all the views expressed in this report accurately reflect their personal views about the subject investment theme and/or company securities.

Although every attempt has been made to verify the accuracy of the information contained in the document, liability for any errors or omissions (except any statutory liability which cannot be excluded) is specifically excluded by Laverne and Banyan Tree, its associates, officers, directors, employees, and agents.  Except for any liability which cannot be excluded, Laverne and Banyan Tree, its directors, employees and agents accept no liability or responsibility for any loss or damage of any kind, direct or indirect, arising out of the use of all or any part of this material.  Recipients of this document agree in advance that Laverne and Banyan Tree are not liable to recipients in any matters whatsoever otherwise; recipients should disregard, destroy or delete this document. All information is correct at the time of publication. Laverne and Banyan Tree do not guarantee reliability and accuracy of the material contained in this document and are not liable for any unintentional errors in the document.

The securities of any company(ies) mentioned in this document may not be eligible for sale in all jurisdictions or to all categories of investors. This document is provided to the recipient only and is not to be distributed to third parties without the prior consent of Laverne and Banyan Tree.